Statistics for Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging
Total visits
views | |
---|---|
Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging | 68 |
Total visits per month
views | |
---|---|
August 2024 | 0 |
September 2024 | 0 |
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 1 |
February 2025 | 0 |
File Visits
views | |
---|---|
Lowe2021Donanemab-CCBY.pdf | 1490 |
java.util.UUID:24aa5e61-003d-4683-a331-f7ed2c57c88b | 484 |
java.util.UUID:be25737c-f30e-4f2b-a363-4fa37e978648 | 17 |
java.util.UUID:23adb036-2e0b-4de6-b563-88379ed83b8f | 14 |
Top country views
views | |
---|---|
United States | 58 |
China | 1 |
India | 1 |
South Korea | 1 |
Top city views
views | |
---|---|
Wilmington | 42 |
Ann Arbor | 5 |
Ashburn | 1 |
Baltimore | 1 |
Cambridge | 1 |
Fairfield | 1 |
Houston | 1 |
Hyderabad | 1 |
Lake Mary | 1 |
Mount Laurel | 1 |
Reston | 1 |
Seodaemun-gu | 1 |
Tustin | 1 |
Washington | 1 |